EA201992130A1 - Usl-1 для применения в лечении злокачественной опухоли - Google Patents

Usl-1 для применения в лечении злокачественной опухоли

Info

Publication number
EA201992130A1
EA201992130A1 EA201992130A EA201992130A EA201992130A1 EA 201992130 A1 EA201992130 A1 EA 201992130A1 EA 201992130 A EA201992130 A EA 201992130A EA 201992130 A EA201992130 A EA 201992130A EA 201992130 A1 EA201992130 A1 EA 201992130A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
usl
malignant tumor
diazepan
propan
Prior art date
Application number
EA201992130A
Other languages
English (en)
Russian (ru)
Inventor
Питер Ричардсон
Original Assignee
Проксимэйджен, Элэлси
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Проксимэйджен, Элэлси filed Critical Проксимэйджен, Элэлси
Publication of EA201992130A1 publication Critical patent/EA201992130A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA201992130A 2017-03-10 2018-03-09 Usl-1 для применения в лечении злокачественной опухоли EA201992130A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1703907.4A GB201703907D0 (en) 2017-03-10 2017-03-10 Novel therapies for cancer
PCT/GB2018/050608 WO2018162924A1 (en) 2017-03-10 2018-03-09 Usl-311 for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
EA201992130A1 true EA201992130A1 (ru) 2020-02-04

Family

ID=58605592

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992130A EA201992130A1 (ru) 2017-03-10 2018-03-09 Usl-1 для применения в лечении злокачественной опухоли

Country Status (14)

Country Link
US (1) US20200281937A1 (cg-RX-API-DMAC7.html)
EP (1) EP3592356A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020514345A (cg-RX-API-DMAC7.html)
KR (1) KR20190128660A (cg-RX-API-DMAC7.html)
CN (1) CN110520130A (cg-RX-API-DMAC7.html)
AU (1) AU2018231664A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019018482A2 (cg-RX-API-DMAC7.html)
CA (1) CA3055470A1 (cg-RX-API-DMAC7.html)
EA (1) EA201992130A1 (cg-RX-API-DMAC7.html)
GB (1) GB201703907D0 (cg-RX-API-DMAC7.html)
IL (1) IL269121A (cg-RX-API-DMAC7.html)
MX (1) MX2019010679A (cg-RX-API-DMAC7.html)
SG (1) SG11201908166UA (cg-RX-API-DMAC7.html)
WO (1) WO2018162924A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
JP6927882B2 (ja) 2015-04-02 2021-09-01 プロキシマジェン,リミティド ライアビリティ カンパニー 癌の新治療法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201017345D0 (en) * 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
EP3030322A2 (en) * 2013-08-05 2016-06-15 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
JP6927882B2 (ja) * 2015-04-02 2021-09-01 プロキシマジェン,リミティド ライアビリティ カンパニー 癌の新治療法
GB201604213D0 (en) * 2016-03-11 2016-04-27 Proximagen Ltd Drug combination and its use in therapy

Also Published As

Publication number Publication date
MX2019010679A (es) 2020-02-05
JP2020514345A (ja) 2020-05-21
IL269121A (en) 2019-11-28
AU2018231664A1 (en) 2019-09-26
WO2018162924A1 (en) 2018-09-13
EP3592356A1 (en) 2020-01-15
CN110520130A (zh) 2019-11-29
GB201703907D0 (en) 2017-04-26
SG11201908166UA (en) 2019-10-30
BR112019018482A2 (pt) 2020-04-14
CA3055470A1 (en) 2018-09-13
US20200281937A1 (en) 2020-09-10
KR20190128660A (ko) 2019-11-18

Similar Documents

Publication Publication Date Title
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1120941T1 (el) Παραγωγα φαινυλοτριαζολιου υποκατεστημενα με υδροξυαλκυλιο και χρησεις αυτων
MX2020008559A (es) Compuestos heterocíclicos como inhibidores de la quinasa.
EA201790546A1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
JP2016533366A5 (cg-RX-API-DMAC7.html)
BR112018008714A2 (pt) inibidores de isoindolina, azaisoindolina, dihidroindenona e dihidroazaindenona da mnk1 e mnk2
SG10201902664RA (en) Combination therapy for treating cancer
EA201692513A1 (ru) Ингибиторы лизин-специфической деметилазы-1
CL2017000589A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret)
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
EA201790376A1 (ru) Ингибиторы лизин-специфической деметилазы-1
TN2016000094A1 (en) Inhibitors of bruton's tyrosine kinase.
PH12019501896A1 (en) Therapeutic dendrimers
MX2020003126A (es) Derivados de iminopirimidina ciclicos como inhibidores de cinasa.
EA201790085A1 (ru) Ингибиторы лизин-специфической деметилазы-1
MX375752B (es) Inhibidores de tirosina quinasa de bruton.
TN2017000158A1 (en) Carbazole derivatives
EA202090497A1 (ru) Соединения и композиции для лечения гематологических нарушений
MX377817B (es) Terapias novedosas para cancer.
EA201591781A1 (ru) Химические соединения
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
MX2018008362A (es) Derivados de quinolin-2-ona.
TN2015000529A1 (en) Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors
BR112018067938A2 (pt) combinação de um antagonista de cxcr4 e inibidor de ponto de verificação imunológica
EA201101651A1 (ru) Непрерывное введение интегриновых лигандов для лечения рака